<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We retrospectively examined the frequency of <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> in Japanese patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in relation to use of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Among a total of 663 patients identified to be taking <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, 9 had <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> (1.36%) </plain></SENT>
<SENT sid="2" pm="."><plain>Overall the hazard ratio of 1.75 [95% CI: 0.89-3.45] for <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> for <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> was not significant </plain></SENT>
<SENT sid="3" pm="."><plain>However the prevalence of <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> was 2.10% in patients taking <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> for less than 24 months which was significant increased (HR 2.73 [95% CI: 1.11-6.72]) </plain></SENT>
</text></document>